InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,010.60
(
0.00%
)
US TECH 100
16,779.20
(
0.16%
)
Dow Jones
38,239.98
(
0.00%
)
Brent Oil
85.52
(
-1.04%
)
Bitcoin
66,010.38
(
-1.27%
)
Post# of 1861
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Penny Roger$

Send PM Follow Ignore
Followers 1106
Posts 279775
Boards Moderated 10
Alias Born 03/18/2011

Penny Roger$

Re: None

Thursday, 01/14/2016 3:42:48 PM

Thursday, January 14, 2016 3:42:48 PM

Post# of 1861
$IMNP ~ Eotaxin-1 causes eosinophils (a type of white blood cell involved in inflammation and allergy) to migrate towards sites of inflammation where they become activated and release substances that result in tissue damage and enhance inflammation. By blocking the effects of eotaxin-1 on eosinophil function, Bertilimumab is a promising clinical stage candidate for a variety of inflammatory conditions, including Ulcerative Colitis, Crohn’s disease, Severe Asthma and Bullous Pemphigoid.

http://www.immunepharma.com/product-portfolio/bertilimumab-draft/

$IMNP Website: http://www.immunepharmaceuticals.com/
$IMNP News: http://finance.yahoo.com/q/h?s=IMNP+Headlines
$IMNP Live Chart: http://stockcharts.com/c-sc/sc?s=IMNP&p=d&b=7&g=0&i=p87425001600

Do your DD! Spend only the money you can afford to lose, while still willing to play at other tables. Commissions are cheaper than losses!

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up